Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:P14/ARF-positive malignant pleural mesothelioma : ǂa ǂphenotype with distinct immune microenvironment
Authors:ID Pezzuto, Federica (Author)
ID Lunardi, Francesca (Author)
ID Vedovelli, Luca (Author)
ID Fortarezza, Francesco (Author)
ID Urso, Loredana (Author)
ID Grosso, Federica (Author)
ID Ceresoli, Giovanni Luca (Author)
ID Kern, Izidor, Klinika Golnik (Author)
ID Vlačić, Gregor, Klinika Golnik (Author)
ID Calabrese, Fiorella (Author)
Files:.pdf PDF - Presentation file, download (13,14 MB)
MD5: 4A36A4ECD95DDC8C8E219734C590DB29
 
URL URL - Source URL, visit https://www.frontiersin.org/articles/10.3389/fonc.2021.653497/full
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Introduction: The CDKN2A gene plays a central role in the pathogenesis of malignant pleural mesothelioma (MPM). The gene encodes for two tumor suppressor proteins, p16/INK4A and p14/ARF, frequently lost in MPM tumors. The exact role of p14/ARF in MPM and overall its correlation with the immune microenvironment is unknown. We aimed to determine whether there is a relationship between p14/ARF expression, tumor morphological features, and the inflammatory tumor microenvironment. Methods: Diagnostic biopsies from 76 chemo-naive MPMs were evaluated. Pathological assessments of histotype, necrosis, inflammation, grading, and mitosis were performed. We evaluated p14/ARF, PD-L1 (tumor proportion score, TPS), and Ki-67 (percentage) by immunohistochemistry. Inflammatory cell components (CD3+, CD4+, CD8+ T lymphocytes; CD20+ B-lymphocytes; CD68+ and CD163+ macrophages) were quantified as percentages of positive cells, distinguishing between intratumoral and peritumoral areas. The expression of p14/ARF was associated with several clinical and pathological characteristics. A random forest-based machine-learning algorithm (Boruta) was implemented to identify which variables were associated with p14/ARF expression. Results: p14/ARF was evaluated in 68 patients who had a sufficient number of tumor cells. Strong positivity was detected in 14 patients (21%) (11 epithelioid and 3 biphasic MPMs). At univariate analysis, p14/ARF-positive epithelioid mesotheliomas showed higher nuclear grade (G3) (p = 0.023) and higher PD-L1 expression (≥50%) (p = 0.042). The percentages of CD4 and CD163 in peritumoral areas were respectively higher and lower in p14/ARF positive tumors but did not reach statistical significance with our sample size (both p = 0.066). The Boruta algorithm confirmed the predictive value of PD-L1 percentage for p14/ARF expression in all histotypes. Conclusions: p14/ARF-positive epithelioid mesotheliomas may mark a more aggressive pathological phenotype (higher nuclear grade and PD-L1 expression). Considering the results regarding the tumor immune microenvironment, p14/ARF-negative tumors seem to have an immune microenvironment less sensitive to immune checkpoint inhibitors, being associated with low PD-L1 and CD4 expression, and high CD163 percentage. The association between p14/ARF-positive MPMs and PD-L1 expression suggests a possible interaction of the two pathways. Confirmation of our preliminary results could be important for patient selection and recruitment in future clinical trials with anticancer immunotherapy.
Keywords:lung -- cytology -- pathology, neoplasms, malignant mesothelioma, malignant pleural mesothelioma, tumor microenvironment
Publication status:Published
Publication version:Version of Record
Place of publishing:Švica
Publisher:Frontiers
Year of publishing:2022
Number of pages:str. 30-39
Numbering:Vol. 11
PID:20.500.12556/DiRROS-15122 New window
UDC:616
ISSN on article:2234-943X
DOI:10.3389/fonc.2021.653497 New window
COBISS.SI-ID:103281667 New window
Copyright:© 2021 Pezzuto, Lunardi, Vedovelli, Fortarezza, Urso, Grosso, Ceresoli, Kern, Vlacic, Faccioli, Schiavon, Gregori, Rea, Pasello and Calabrese
Note:Nasl. z nasl. zaslona; Soavtorja iz Slovenije: Izidor Kern, Gregor Vlačić; Opis vira z dne 4. 4. 2022;
Publication date in DiRROS:30.05.2022
Views:782
Downloads:506
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Frontiers in oncology
Shortened title:Front. oncol.
Publisher:Frontiers Editorial Office
ISSN:2234-943X
COBISS.SI-ID:1601583 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:22.03.2022

Secondary language

Language:Undetermined
Keywords:pljuča --citologija -- patologija, novotvorbe, maligni mezoteliom, maligni plevralni mezoteliom, tumorsko mikrookolje


Back